Acquisition of DeSC Healthcare as a Subsidiary and Database Integration
First written in FY2022. 8 of 13 entries say "Advanced", first in FY2023-Q3. Latest entry: 2026-08-05.
6 other companies' latest entry also says "Advanced".
- 2026-08-05AdvancedEarnings presentation
「89 transacting customers, versus 68 in the same period of the previous year (+31%), and transaction value per customer among the top 20 customers +7.5%. The growth trend continues, supported by the sales organization and expanded solutions.」
For its data utilization services, the Company presented continued growth using specific metrics for transacting customers, transaction value per top customer, and the sales and solutions organization. - FY2026AdvancedAnnual report
「The number of customers transacting with us during the latest 12 months through March 2026 was 94, including 43 pharmaceutical companies and others, up from 69, including 32 pharmaceutical companies and others, in the same period of the previous year. The transaction value per customer among the top 20 customers also increased 25% year on year.」
The number of trading companies using the data utilization service increased from 69 to 94 over the most recent 12 months, the number of pharmaceutical companies and other such companies increased from 32 to 43, and the transaction value per customer among the top 20 customers also increased 25% year on year. - 2026-05-12AdvancedManagement plan
「Development and implementation of an AI model for predicting the likelihood of undergoing specific health checkups, with revenue already recognized in the fiscal year ending March 2026」
The Company commercialized AI applications in both its data utilization and data health businesses, recognizing revenue from the checkup-likelihood prediction AI and beginning joint RWD × AI development. - FY2025AdvancedAnnual report
「The number of solution customers over the 12 months ended March 2025 reached 69, including 32 pharmaceutical companies and other such companies, with a cumulative track record of more than 290 conference presentations and published papers.」
The number of trading companies using the data utilization service over the most recent 12 months reached 69, including 32 pharmaceutical companies and other such companies, and a cumulative total of more than 290 conference presentations and published papers has been disclosed. - FY2025-H1AdvancedAnnual report
「Demand from customers for the Group's solutions remains strong in the data utilization services business, and sales activities during the year toward orders concentrated in March have progressed steadily. Strong growth is expected in the current fiscal year and thereafter. The number of companies doing business with us during the most recent 12 months through 31 December 2024 was 64, including 28 pharmaceutical companies and other such companies, up steadily from 50 in the same period of the previous year, including 28 pharmaceutical companies and other such companies. The transaction amount per customer also increased by 13% year on year.」
For the data utilization service, sales activities targeting orders concentrated in March have progressed, and the number of trading companies over the most recent 12 months increased from 50 in the same period of the previous year to 64. The transaction value per customer also increased 13% year on year. - FY2024AdvancedAnnual report
「For the consolidated fiscal year, revenue from data utilization services was ¥1,031.588 million.」
For the data utilization services business launched through cooperation with DeSC, full-year revenue of ¥1,031 million and year-on-year growth of 131.2% have been disclosed. - FY2024-Q3AdvancedAnnual report
「In terms of earnings, the former Group became profitable through higher revenue from its high-margin data health planning support services, and operating profit increased by ¥374 million year on year. In the current consolidated results including DeSC, however, revenue from data utilization services increased by ¥227 million from the same period of the previous year, but continued active investment and ¥192 million in goodwill amortization expense, among other costs, weighed heavily on earnings, resulting in an operating loss of ¥422 million, compared with an operating loss of ¥369 million in the same period of the previous year.」
Revenue from data utilization services after the consolidation of DeSC increased by ¥227 million year on year, but continued active investment and ¥192 million in goodwill amortization expense, among other factors, resulted in an operating loss of ¥422 million. - FY2024-Q2Update on post-consolidation results and amortization expenseAnnual report
「In terms of earnings, the former Group reduced its operating loss by ¥268 million through higher revenue from its high-margin data health planning support services. In the current consolidated results including DeSC, however, the operating loss was ¥445 million, compared with an operating loss of ¥461 million in the same period of the previous year, due mainly to the concentration of revenue from data utilization services in the second half of the fiscal year and ¥128 million in amortization of goodwill.」
Following the consolidation of DeSC, revenue from data utilization services is concentrated in the second half of the fiscal year, and ¥128 million in goodwill amortization expense was incurred during the cumulative second quarter. - FY2024-Q1Details on the timing of revenue recognitionAnnual report
「In terms of earnings, the former group returned to profitability on higher sales generated by its high-margin data health planning support business. Following the consolidation of DeSC as a subsidiary, however, sales from data utilization services became concentrated in the second half of the fiscal year, while amortization of goodwill amounted to ¥64 million, among other factors. As a result, operating loss was ¥226 million, compared with an operating loss of ¥108 million in the same period of the previous year, ordinary loss was ¥218 million, compared with an ordinary loss of ¥224 million, and quarterly net loss attributable to owners of the parent was ¥224 million, compared with a quarterly net loss of ¥168 million.」
The data utilization services business following DeSC becoming a subsidiary has been specifically described as having a structure in which revenue is concentrated in the second half of the fiscal year. - FY2023-Q3AdvancedAnnual report
「Revenue from the data utilization business launched in cooperation with DeSC from the previous fiscal year was ¥692 million, representing steady growth.」
For the data utilization business following DeSC becoming a subsidiary, revenue of ¥692 million for the cumulative third quarter has been disclosed, and the business is described as growing steadily. - FY2023-Q2RestatedAnnual report
「On 3 October 2022, we acquired shares of DeSC Healthcare from DeNA Co.,Ltd. and have included the company as a consolidated subsidiary from the second quarter of the consolidated fiscal year under review. Going forward, we aim for stable growth in our data health-related business and the strong launch of our new data utilization business.」
The policy of pursuing stable growth in the data health-related business and launching the data utilization business, based on the acquisition and consolidation of DeSC, has been reconfirmed. - FY2023-Q1AchievedAnnual report
「On 3 October 2022, we acquired all shares of DeSC Healthcare held by DeNA Co.,Ltd. (hereinafter, "DeSC").」
On 3 October 2022, shares of DeSC Healthcare were acquired and the company became a consolidated subsidiary. The acquired voting interest was 95%, and the plan to integrate the two companies' databases and create an insurer database covering all generations has moved to the implementation stage. - FY2022First statedAnnual report
「We concluded that it was necessary for us to make DeSC Healthcare a subsidiary in order to further strengthen cooperation between our company and DeSC, integrate the two companies' databases, accelerate initiatives for a public-interest data utilization business based on an insurer database covering all generations from health insurance societies to municipalities, and expand our share of that market.」
The plan to make DeSC Healthcare a subsidiary with a 95% voting interest on 1 October 2022, integrate the two companies' databases and create an insurer database covering all generations has been described in specific terms for the first time.